- Companies
- Neuralink
Neuralink Valuation, Funding & Investors
Neuralink is valued at $9B as of May 2025.
Last Neuralink valuation
$9B
Series E · May 2025
Last Neuralink funding round
Undisclosed stage
Amount undisclosed · May 2026
Cumulative funding Neuralink raised
$1.3B
across 6 funding rounds
Key investors in Neuralink
Founders Fund
Vy Capital
Sequoia Capital
Lightspeed Venture Partners
Thrive Capital
Valor Equity Partners
About Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a group of scientists and engineers, focused on developing implantable brain–computer interface (BCI) devices. Its primary product, the N1 chip, is surgically implanted into the skull by a precision robotic system called R1, enabling direct communication between the human brain and external computers or devices. The company's stated mission is to address neurological conditions such as paralysis, blindness, and severe motor impairments, allowing patients to control digital devices using thought alone. In January 2024, Neuralink implanted its first BCI device in a human patient, with the individual subsequently demonstrating the ability to control a computer cursor through neural signals. Headquartered in Fremont, California, the company operates at the intersection of neuroscience, robotics, and semiconductor engineering, and has attracted significant attention for its long-term ambitions around human-AI symbiosis.
Founded
2016
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$9B (May 2025)
Neuralink Valuation
Neuralink is currently valued at $9B, based on its Series E in May 2025.
The $649M round included Qatar Investment Authority, G42 Expansion Fund, Human Capital, DFJ Growth, Sequoia Capital and 7 other investors.
Neuralink's valuation has grown 4.5x from $2B at its Series C in July 2021 to $9B in May 2025, across 3 priced rounds.
Neuralink valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| May 2025 | Series E | $9B |
| Aug 2023 | Series D | $3.4B |
| Jul 2021 | Series C | $2B |
Neuralink Funding History
Neuralink has raised a total of $1.3B across 6 funding rounds.
Neuralink's first fundraising round was a $107M Series A in August 2017. The most recent completed round was a undisclosed-stage round in May 2026.
Neuralink funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| May 2026 | Undisclosed stage | Oman Investment Fund (lead) | - | - | - |
| May 2025 | Series E | Qatar Investment Authority; G42 Expansion Fund; Human Capital; DFJ Growth; Sequoia Capital; Lightspeed Venture Partners; ARK Investment Management; Founders Fund; Valor Equity Partners; K2 Global; Thrive Capital; Vy Capital | $649M | $9B | Neuralink, Elon Musk's brain-computer interface startup, develops implantable devices like the N1 implant, a coin-sized brain chip with 1,024 electrodes that enables quadriplegic patients to control computers using thoughts. The implant is surgically placed via the R1 robot, which uses cameras and optical coherence tomography for precision. As of mid-2025, Neuralink had implanted the device in five patients and received FDA Breakthrough Device designation for additional implants targeting vision and speech restoration. The company conducts clinical trials in partnership with universities and aims to expand patient access. In May-June 2025, Neuralink closed a $650 million Series E funding round with investors including ARK Investment Management, Founders Fund, Sequoia Capital, Lightspeed Venture Partners, Thrive Capital. Sources including Semafor, SiliconAngle, and TechCrunch reported a $9 billion pre-money valuation, more than double the prior $3.5B-$5B valuation from 2023 rounds. Earlier Bloomberg reporting noted fundraising targets of $500M at $8.5B pre-money. The round followed Neuralink's Series D of $280M plus $43M in 2023. Proceeds will fund hardware development, engineer hiring, and clinical expansion. Neuralink's progress includes human trials showing capabilities like a nonverbal ALS patient using the implant to edit and narrate YouTube videos. The company remains pre-commercial with focus on R&D and regulatory milestones amid competition in brain interfaces. |
| Aug 2023 | Series D | Founders Fund (lead); Meros Equity Global Management; IPO CLUB; Soul Ventures; MarketX Ventures; Advaita Capital; Setcoin Group; Oak Grove Ventures; Type One Ventures | $323M | $3.4B | Neuralink, co-founded by Elon Musk in 2016, develops implantable brain-machine interfaces using a sewing machine-like device to insert ultra-thin threads with electrodes into the brain, enabling wireless reading of neural signals for applications like helping paralyzed individuals communicate, restoring sight to the blind, and addressing spinal cord injuries. The company received FDA approval for human clinical trials in May 2023 after initial rejection and has faced scrutiny over animal testing and workplace culture. In early August 2023, Neuralink closed its Series D funding round, initially announced as $280 million and later increased to $323 million per an SEC filing, led by Founders Fund with participation from 32 investors including Advaita Capital, IPO CLUB, MarketX Ventures, Meros Equity Global Management, Oak Grove Ventures, Setcoin Group, Soul Ventures, and Type One Ventures. The round was authorized on August 1, 2023, at a post-money valuation of $3.4 billion, up 55.7% from the prior $2.2 billion Series C valuation in 2021, based on a $19.03 per share price. This marked Neuralink's fourth funding round following Series A ($27M in 2017), Series B ($39.3M in 2019), and Series C ($205.9M in 2021 led by Vy Capital with Google Ventures and others). The funds supported expansion of production, acceleration of vision restoration research, and progression toward human trials after FDA clearance. Privately executed stock trades in June 2023 valued the company at $5 billion according to Reuters, though this was not tied directly to the Series D terms. Neuralink operates in a competitive neurotechnology field, with rivals like Synchron advancing US clinical trials ahead of it, amid $143 million invested in similar startups through mid-2023. Subsequent developments included a $43 million extension to the Series D in November 2023 and a $650 million Series E in May 2025 at $9 billion valuation, but these post-date the queried round. |
| Jul 2021 | Series C | Vy Capital (lead) | $205M | $2B | Neuralink, founded in 2016 by Elon Musk, is developing implantable brain-computer interface technology designed to enable direct communication between the human brain and external devices. The company's flagship product, the N1 Link, is a 1024-channel wireless brain implant intended to help individuals with paralysis regain digital freedom by allowing them to control computers and smartphones through thought alone. The device aims to address neurological conditions including spinal cord injuries, paralysis, memory loss, hearing loss, and blindness. In July 2021, Neuralink announced a $205 million Series C funding round led by Vy Capital, with participation from Google Ventures, DFJ Growth, Valor Equity Partners, Craft Ventures, Founders Fund, and Gigafund. This round valued the company at $2 billion post-money and was directed toward refining the N1 Implant and preparing for early-stage human clinical trials. The funding represented a significant milestone as the company advanced its development toward human testing and commercialization of its brain-machine interface technology. |
| Apr 2019 | Series B | Ironwood Ventures; Craft Ventures | $51M | - | Neuralink, founded by Elon Musk, develops implantable brain-machine interfaces to treat neurological conditions and enhance human cognition through high-bandwidth connections between the brain and computers. The company raised $51 million in April 2019 from investors including Craft Ventures and Ironwood Ventures, listed as part of early Series C activity, aimed at advancing device safety trials and expanding engineering teams. A separate Series C round of $205 million followed in July 2021 with lead investors like Vy Capital, Google Ventures, and Craft Ventures to refine the N1 Implant and prepare for human clinical trials. Total funding across rounds exceeds $1.29 billion as of May 2025. Key backers include Founders Fund, Google Ventures (GV), Sequoia Capital, and ARK Investment Management. Neuralink has progressed to human trials, receiving FDA breakthrough device clearance, with three patients implanted; one nonverbal patient demonstrated controlling YouTube video editing and narration via brain signals. Future plans focus on expanding trials for the N1 Implant, developing Blindsight for vision restoration, and pursuing broader FDA approvals for medical and cognitive enhancement applications in the brain-computer interface space. |
| Aug 2017 | Series A | UpHonest Capital | $107M | - | Neuralink, founded in 2016 by Elon Musk, develops brain-computer interface (BCI) implants like the N1 device for paralysis patients, enabling thought-based control of computers, with ongoing clinical trials and expansions into vision and speech restoration. Recent funding includes $600M in May 2025 at $9-9.6B valuation, $650M Series E in 2025 at $9B pre-money, $280M in 2023, and $43M in Nov 2023 at $3.5B valuation, with investors like Founders Fund, Sequoia, ARK Invest, and others; total raised exceeds $1.2B. |
Who has invested in Neuralink?
24 investors have backed Neuralink across its funding rounds, including Founders Fund, Vy Capital, Sequoia Capital, Lightspeed Venture Partners, Thrive Capital and Valor Equity Partners.
Lead investors include Oman Investment Fund, Founders Fund and Vy Capital.
Neuralink Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Aug 2023 | ||
| 2 | Lead | Jul 2021 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | May 2025 | ||
| 1 | Lead | May 2026 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | May 2025 | ||
| 1 | Participant | Aug 2023 | ||
| 1 | Participant | May 2025 | ||
| 1 | Participant | May 2025 | ||
| 1 | Participant | May 2025 | ||
This data is available for Pro users. Sign up to see all 24 Neuralink investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialNeuralink Competitors
Neuralink competitors include listed companies like UBtech Robotics and Insulet, and private ones like CMR Surgical, Saronic, Quantum Systems and SambaNova.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $3B | - | ||
| Publicly listed | $298M | ($108M) | $5.1B | 9.5x | ||
| Private | $200M | - | $9.3B | 46.3x | ||
| Publicly listed | $2.7B | $455M | $9.8B | 3.3x | ||
| Private | $330M | - | $8B | 24.2x | ||
| Private | $100M | - | $11B | - |
Neuralink Public Comps
Neuralink is still privately-owned, but its public comps include Aptiv, Caris Life Sciences, Glaukos, Bruker, Demant, Insulet, Globus Medical, Bio-Rad Laboratories, Cooper Companies and Sysmex.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $20B | $2.2B | 0.7x | 0.9x | 6.3x | 5.4x | |||
| $812M | ($5M) | 10.3x | 8.7x | (1640.5x) | 49.4x | |||
| $507M | ($157M) | 18.4x | 14.6x | (59.6x) | 166.3x | |||
| $3.4B | $288M | 3.3x | 3.2x | 39.1x | 18.5x | |||
| $3.5B | $782M | 3.6x | 3.2x | 16.1x | 13.5x | |||
| $2.7B | $455M | 3.8x | 3.3x | 22.5x | 13.5x | |||
| $2.9B | $875M | 3.2x | 3.0x | 10.8x | 9.1x | |||
| $2.6B | $1.1B | 3.8x | 3.8x | 8.9x | 22.8x | |||
This data is available for Pro users. Sign up to see all Neuralink competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Neuralink
| When was Neuralink founded? | Neuralink was founded in 2016. |
| Where is Neuralink headquartered? | Neuralink is headquartered in United States. |
| Is Neuralink publicly listed? | No, Neuralink is a private, VC-backed company. |
| What is Neuralink's valuation? | Neuralink was last valued at $9B in its Series E in May 2025. |
| How much funding has Neuralink raised? | Neuralink has raised $1.3B across 6 funding rounds. |
| What was Neuralink's last funding round? | Neuralink's last funding round was a undisclosed-stage round in May 2026, led by Oman Investment Fund. |
| Who are Neuralink's investors? | Neuralink's investors include Founders Fund, Vy Capital, Meros Equity Global Management, IPO CLUB, Soul Ventures, Qatar Investment Authority, Oman Investment Fund, MarketX Ventures, G42 Expansion Fund, Advaita Capital and 14 others. |
| Which companies are comparable to Neuralink? | Companies comparable to Neuralink include CMR Surgical, UBtech Robotics, Saronic, Insulet, Quantum Systems and SambaNova. |
See companies similar to Neuralink
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




